Concept: American data center startup Ilumio and domestic medical device security startup Cylera, have collaborated to create an integrated cyber risk solution for healthcare providers. The duo aims to minimize the risk of catastrophic breaches and ransomware attacks while also speeding up the implementation of Zero Trust security for healthcare providers around the world.
Nature of Disruption: Cylera’s asset-centric security technology is combined with Illumio’s Zero Trust Segmentation. Healthcare providers can obtain a holistic picture of risks and take proactive measures to apply segmentation within and across the two types of networks by merging Illumio’s IT network map with Cylera’s medical device map and vulnerability analysis in a single view. Cylera’s asset-centric security platform uses patented capabilities to discover, assess, and mitigate threats associated with linked medical, IoT, and OT (Operational Technology) devices in healthcare networks. With Cylera’s network and agentless methodology, all linked devices can be monitored without affecting operations or services. The digital twin strategy produces precise asset inventories, better risk analysis, significantly enhanced threat intelligence about devices, and reduces the time IT security teams spend mitigating risks. Ransomware mitigation and Zero Trust Segmentation solutions from Illumio can prevent lateral movement and contain breaches before they spread and become catastrophic.
Outlook: The attack surface has widened in a highly complicated and hybrid world, making it easier than ever for attacks to penetrate, bringing larger economic risks across the corporation. Most healthcare organizations lack visibility into their IT network, and far less insight into their diversified inventory of medical IoT and OT devices, as well as how these systems interact. With the surge in ransomware attacks against healthcare providers, Cylera’s integration with Illumio can assist business customers to understand and mitigate their risks. Their technologies can considerably complement one another, providing healthcare practitioners with the unified visibility and control they require.
Verdict deals analysis methodology
This analysis considers only announced and completed artificial intelligence deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.